Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US

Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US

Jay Lin,1 Melissa Lingohr-Smith,1 Tao Fan2 1Health Economics and Outcomes Research, Novosys Health, Green Brook, NJ, USA; 2North America Medical Affairs, Sanofi US, Inc., Bridgewater, NJ, USA Background: Free-dose combination treatment with basal insulin and short-acting glucagon-like pepti...

Full description

Bibliographic Details
Main Authors: Lin J, Lingohr-Smith M, Fan T
Format: Article
Language:English
Published: Dove Medical Press 2016-12-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Basal insulin
GLP-1 receptor agonist
treatment persistence
type 2 diabetes
Online Access:https://www.dovepress.com/real-world-medication-persistence-and-outcomes-associated-with-basal-i-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/real-world-medication-persistence-and-outcomes-associated-with-basal-i-peer-reviewed-article-CEOR

Similar Items